# Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma

> **NCT00231166** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 33 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** HCD122

## Key facts

- **NCT ID:** NCT00231166
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2018-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00231166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00231166, "Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00231166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*